Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide interactions

Checked as Adenosine + Nicotinamide in this data source.

Full monograph for Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide Check it against another medicine

Medicines

332 documented

Severity

Mechanism

Medicines documented to interact with Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Amiodarone Hydrochloridevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Amisulpridevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Arsenic Trioxidevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Artemether + Lumefantrinevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…2 documented mechanisms	25 sources — open the full entry
Cabozantinibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Ceritinibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Citalopram Hydrobromidevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Clozapinevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Crizotinibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Digoxinvia Adenosine	Major	Synergy	The use of adenosine in patients receiving digitalis glycosides may increase the risk of ventricular fibrillation. Rare cases of ventricular fibrillation…	12 sources — open the full entry
Efavirenzvia Nicotinamide, Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…2 documented mechanisms	24 sources — open the full entry
Escitalopram Oxalatevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Gatifloxacinvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Gatifloxacin + Dexamethasonevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Haloperidolvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Iloperidonevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Ivosidenibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Lefamulin Acetatevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Leflunomidevia Nicotinamide	Major	Synergy	The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may…	3 sources — open the full entry
Loteprednol Etabonate + Gatifloxacinvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Mifepristonevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Mifepristone + Misoprostolvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Moxifloxacin HydrochlorideInjection Ophthalmic Tabletvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Moxifloxacin Hydrochloride + Dexamethasonevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Moxifloxacin Hydrochloride + Xanthan Gumvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Nilotinibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Osimertinibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Quinine Sulfatevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Ribociclibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Selpercatinibvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Sotalol Hydrochloridevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Sparfloxacinvia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Ziprasidonevia Adenosine	Major	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	17 sources — open the full entry
Abiraterone Acetatevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Acarbosevia Nicotinamide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Alfuzosin Hydrochloridevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Alogliptin Benzoatevia Nicotinamide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Aminophyllinevia Adenosine	Moderate	Antagonism	INTERVAL: Methylxanthines (e.g., caffeine, theophylline) are nonspecific, competitive antagonists of adenosine receptors. As such, they may interfere with the…	10 sources — open the full entry
Amitriptyline Hydrochloridevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Amitriptyline Hydrochloride + Chlordiazepoxidevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Apalutamidevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Asenapine Maleatevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Aspirin + Dipyridamolevia Adenosine	Moderate	Synergy · Unknown	Dipyridamole potentiates the effects of adenosine. The mechanism probably is inhibition of endogenous and exogenous adenosine reuptake, which increases plasma…2 documented mechanisms	16 sources — open the full entry
Atomoxetine Hydrochloridevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Azithromycin Dihydratebase Ophthalmicvia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Bicalutamidevia Adenosine	Moderate	Synergy	Adenosine has induced torsade de pointes arrhythmia in patients with preexisting long QT syndrome. Theoretically, coadministration of adenosine with agents…	18 sources — open the full entry
Biphasic Insulin Aspartvia Nicotinamide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	85 sources — open the full entry
Caffeine Citratevia Adenosine	Moderate	Antagonism	INTERVAL: Methylxanthines (e.g., caffeine, theophylline) are nonspecific, competitive antagonists of adenosine receptors. As such, they may interfere with the…	10 sources — open the full entry
Canagliflozin Hemihydratevia Nicotinamide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Carbamazepinevia Nicotinamide, Adenosine	Moderate	Metabolism · Synergy	Carbamazepine has been reported to increase the degree of heart block produced by other agents, including adenosine. In vitro data show that carbamazepine…2 documented mechanisms	15 sources — open the full entry

Food & lifestyle

coffee
Moderate
Antagonism
Caffeine and other xanthine derivatives (e.g., theophylline) are nonspecific, competitive antagonists of adenosine receptors and may interfere with the hemodynamic effects of adenosine.
What to do: Clinicians should be aware that adenosine may be less effective in the presence of xanthine derivatives including caffeine. Patients should avoid consumption of caffeine-containing products for at least 12 hours, preferably 24 hours, prior to administration of adenosine for myocardial perfusion imaging.
6 sources
1. Conti CR "Adenosine: clinical pharmacology and applications." Clin Cardiol 14 (1991): 91-3
2. Smits P, Schouten J, Thien T "Respiratory stimulant effects of adenosine in man after caffeine and enprofylline." Br J Clin Pharmacol 24 (1987): 816-9
3. Minton NA, Henry JA "Pharmacodynamic interactions between infused adenosine and oral theophylline." Hum Exp Toxicol 10 (1991): 411-8
4. "Product Information. Adenocard (adenosine)." Fujisawa (2001):
5. "Multum Information Services, Inc. Expert Review Panel"
6. "Product Information. Adenoscan (adenosine)." Fujisawa (2001):

Conditions

Conditions in which Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide needs care, as documented in this source.

Arrhythmias, Cardiac
Major
Antiarrhythmic agents can induce or worsen ventricular arrhythmias. Ventricular tachycardia, ventricular fibrillation, and torsades de pointes have occurred in some patients. Patients with underlying cardiac dysfunction, bradycardia, hypokalemia, hypomagnesemia, or high antiarrhythmic serum concentrations are at increased risk for drug-induced arrhythmias. Therapy with antiarrhythmics should be used with extreme caution in patients with or predisposed to arrhythmias. Evidence of improved survival is lacking for use of antiarrhythmic therapy in asymptomatic, non-life-threatening arrhythmias. Therapy with antiarrhythmic agents should be reserved for patients with life-threatening arrhythmias.
62 sources
1. Anderson JL, Popat KD "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy." Arch Intern Med 141 (1981): 801-2
2. Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditti A, Agmon J "Amiodarone-induced polymorphous ventricular tachycardia." Am Heart J 105 (1983): 6-12
3. Strasberg B, Sclarovsky S, Erdberg A, et al. "Procainamide-induced polymorphous ventricular tachycardia." Am J Cardiol 47 (1981): 1309-14
4. Stratmann H, Walter K, Kennedy H "Torsade de pointes associated with elevated N-acetylprocainamide levels." Am Heart J 109 (1985): 375-6
5. Lo KS, Gantz KB, Stetson PL, et al. "Disopyramide-induced ventricular tachycardia." Arch Intern Med 140 (1980): 413-4
6. Kinney EL, Field EH, Salmon MP, Zelis R "Cardiac arrhythmias associated with disopyramide." N Engl J Med May (1990): 1146
7. Chia BL "Disopyramide induced atypical ventricular tachycardia." Aust N Z J Med 10 (1980): 665-8
8. Tzivoni D, Keren A, Stern S, Gottlieb S "Disopyramide-induced Torsade de pointes." Arch Intern Med 141 (1981): 946-7
Show all 62 sourcesShow fewer sources
1. Schweitzer P, Mark H "Torsade de pointes caused by disopyramide and hypokalemia." Mt Sinai J Med 49 (1982): 110-4
2. Riccioni N, Castiglioni M, Bartolomei C "Disopyramide-induced QT prolongation and ventricular tachyarrhythmias." Am Heart J 105 (1983): 870-1
3. Andrivet P, Beaslay V, Canh VD "Torsades de pointe with flecainide-amiodarone therapy." Intensive Care Med 16 (1990): 342-3
4. Cocco G, Strozzi C, Chu D, Pansini R "Torsades de pointes as a manifestation of mexiletine toxicity." Am Heart J 100 (1980): 878-80
5. Nora MO, Chandrasekaran K, Hammill SC, Reeder GS "Prolongation of ventricular depolarization: ECG manifestation of mexiletine toxicity." Chest 95 (1989): 925-8
6. Morganroth J, Pratt CM "Prevalence and characteristics of proarrhythmia from moricizine (themozine)." Am J Cardiol 63 (1989): 172-6
7. Damle R, Levine J, Matos J, et al. "Efficacy and risks of moricizine in inducible sustained ventricular tachycardia." Ann Intern Med 116 (1992): 375-81
8. Nathan AW, Hellestrand KJ, Bexton RS, Camm AJ "Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent." Postgrad Med J 60 (1984): 155-6
9. Stavens CS, McGovern B, Garan H, Ruskin JN "Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone." Am Heart J 110 (1985): 24-9
10. Hii JT, Wyse DG, Gillis AM, et al. "Propafenone-induced torsade de pointes: cross-reactivity with quinidine." Pacing Clin Electrophysiol 14 (1991): 1568-70
11. Cheesman M, Ward DE "Exacerbation of ventricular tachycardia by tocainide." Clin Cardiol 8 (1985): 47-50
12. Bauman JL, Bauernfeind RA, Hoff JV, et al. "Torsade de pointes due to quinidine: observations in 31 patients." Am Heart J 107 (1984): 425-30
13. Koenig W, Schinz AM "Spontaneous ventricular flutter and fibrillation during quinidine medication." Am Heart J 105 (1983): 863-5
14. Morganroth J, Horowitz LN "Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias." Am J Cardiol 56 (1985): 585-7
15. Au PK, Bhandari AK, Bream R, et al. "Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia." J Am Coll Cardiol 9 (1987): 389-97
16. Engler RL, LeWinter M "Tocainide-induced ventricular fibrillation." Am Heart J 101 (1981): 494-6
17. Wesley RC Jr, Turnquest P "Torsades de pointe after intravenous adenosine in the presence of prolonged QT syndrome." Am Heart J 123 (1992): 794-6
18. Orebaugh SL, Handy M "Intravenous adenosine therapy accelerating rate of paroxysmal supraventricular tachycardia." Am J Emerg Med 10 (1992): 326-30
19. Reed R, Falk JL, O'Brien J "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med 9 (1991): 566-70
20. Meurer MK "A 21-year-old woman with rapid atrial fibrillation after adenosine administration." J Emerg Nurs 17 (1991): 135-6
21. Dougherty AH, Gilman JK, Wiggins S, Jalal S, Naccarelli GV "Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine." Pacing Clin Electrophysiol 16 (1993): 8-12
22. "Product Information. Tonocard (tocainide)." Merck & Co., Inc (2002):
23. "Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals (2002):
24. "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories (2002):
25. "Product Information. Bretylol (bretylium)." DuPont Pharmaceuticals (2002):
26. "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals (2002):
27. "Product Information. Procan SR (procainamide)." Parke-Davis (2001):
28. "Product Information. Pronestyl (procainamide)." Apothecon Inc (2001):
29. Raehl CL, Patel AK, LeRoy M "Drug-induced torsade de pointes." Clin Pharm 4 (1985): 675-90
30. Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8
31. Sulke AN, Holt P, Sowton GE "Acceleration of conduction within an accessory pathway with propafenone." Int J Cardiol 28 (1990): 105-7
32. "Product Information. Adenocard (adenosine)." Fujisawa (2001):
33. "Product Information. Tambocor (flecainide)." 3M Pharmaceuticals (2001):
34. "Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim (2001):
35. "Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company
36. Ben-Sorek ES, Wiesel J "Ventricular fibrillation following adenosine administration. A case report." Arch Intern Med 153 (1993): 2701-2
37. Said SAM, Somer ST, Luttikhuis HAO "Flecainide-induced JT prolongation, t wave inversion and ventricular tachycardia during treatment for symptomatic atrial fibrillation." Int J Cardiol 44 (1994): 285-7
38. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH "Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs." JAMA 270 (1993): 2590-7
39. "Product Information. Norpace (disopyramide)." Searle (2001):
40. Oberg KC, Otoole MF, Gallastegui JL, Bauman JL "''late'' proarrhythmia due to quinidine." Am J Cardiol 74 (1994): 192-4
41. Romer M, Candinas R "Adenosine-induced non-sustained polymorphic ventricular tachycardia." Eur Heart J 15 (1994): 281-2
42. Hohnloser SH, Klingenheben T, Singh BN "Amiodarone-associated proarrhythmic effects - a review with special reference to torsade de pointes tachycardia." Ann Intern Med 121 (1994): 529-35
43. Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7
44. Exner DV, Muzyka T, Gillis AM "Proarrhythmia in patients with the Wolff-Parkinson-White Syndrome after standard doses of intravenous adenosine." Ann Intern Med 122 (1995): 351-2
45. Williamson BD, Hummel J, Niebauer M, Man C, Strickberger SA, Daoud E, Morady F "Bradycardia-facilitated polymorphic ventricular tachycardia caused by amiodarone after radiofrequency modification of atrioventricular conduction." Am Heart J 130 (1995): 399-401
46. Dhein S, Schott M, Gottwald E, Klaus W "Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study." Naunyn Schmiedebergs Arch Pharmacol 352 (1995): 94-101
47. "Product Information. Cordarone (amiodarone)." Apothecon Inc (2022):
48. Hohnloser SH, Vandeloo A, Baedeker F "Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine." J Am Coll Cardiol 26 (1995): 852-8
49. "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn (2001):
50. Silverman AJ, Machado C, Baga JJ, Meissner MD, Lehmann MH, Steinman RT "Adenosine-induced atrial fibrillation." Am J Emerg Med 14 (1996): 300-1
51. Boriani G, Biffi M, Frabetti L, Azzolini U, Sabbatani P, Bronzetti G, Capucci A, Magnani B "Ventricular fibrillation after intravenous amiodarone in wolff-parkinson-white syndrome with atrial fibrillation." Am Heart J 131 (1996): 1214-6
52. Faggiano P, Gardini A, Daloia A, Benedini G, Giordano A "Torsade de pointes occurring early during oral amiodarone treatment." Int J Cardiol 55 (1996): 205-8
53. Heisler BE, Ferrier GR "Proarrhythmic actions of flecainide in an isolated tissue model of ischemia and reperfusion." J Pharmacol Exp Ther 279 (1996): 317-24
54. Strickberger SA, Man KC, Daoud EG, et al. "Adenosine-induced atrial arrhythmia: a prospective analysis." Ann Intern Med 127 (1997): 417-22
Cardiomyopathies
Major
Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF). Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk. Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF. Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.
17 sources
1. Halkin H, Meffin P, Melmon KL, Rowland M "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther 17 (1975): 669-76
2. Crouthamel WG "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J 90 (1975): 335-9
3. Ravid S, Podrid PJ, Lampert S, Lown B "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol 14 (1989): 1326-30
4. Swiryn S, Kim SS "Quinidine-induced syncope." Arch Intern Med 143 (1983): 314-6
5. Gottlieb SS, Packer M "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J 118 (1989): 611-2
6. Ochs HR, Grube E, Greenblatt DJ, Arendt R "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol 19 (1981): 173-6
7. Prescott LF, Adjepon-Yamoah KK, Talbot RG "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J 1 (1976): 939-41
8. "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories (2002):
Show all 17 sourcesShow fewer sources
1. "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals (2002):
2. "Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories
3. "Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.
4. "Product Information. Adenocard (adenosine)." Fujisawa (2001):
5. "Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim (2001):
6. Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med 78 (1973): 499-508
7. Singh SN, Fletcher RD, Fisher SG, et al. "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med 333 (1995): 77-82
8. "Product Information. Cordarone (amiodarone)." Apothecon Inc (2022):
9. "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn (2001):
Sick Sinus Syndrome
Major
The use of adenosine is contraindicated in patients with second- or third-degree AV block, sick sinus syndrome, or symptomatic bradycardia in the absence of a functional artificial pacemaker.
4 sources
1. Reed R, Falk JL, O'Brien J "Untoward reaction to adenosine therapy for supraventricular tachycardia." Am J Emerg Med 9 (1991): 566-70
2. Engelstein ED, Lerman BB "Adenosine induced intraatrial block." Pacing Clin Electrophysiol 16 (1993): 89-94
3. "Product Information. Adenocard (adenosine)." Fujisawa (2001):
4. Kipel G, Rossi AF, Steinberg LG, Gelb B, Fiumecaldo F, Golinko RJ, Griepp RB "Malignant wide complex tachycardia after adenosine administration to a postoperative pediatric patient with congenital heart disease." Pediatr Cardiol 16 (1995): 36-7
Asthma
Moderate
Adenosine induces mast cell degranulation and histamine release. Bronchoconstriction has been reported in patients with asthma during therapy with adenosine. Therapy with adenosine should be administered cautiously in patients with obstructive lung disease not associated with bronchoconstriction (emphysema or bronchitis) and should be avoided in patients with bronchoconstriction or bronchospasm (asthma).
6 sources
1. "Product Information. Adenocard (adenosine)." Fujisawa (2001):
2. Aggarwal A, Farber NE, Warltier DC "Intraoperative bronchospasm caused by adenosine." Anesthesiology 79 (1993): 1132-5
3. Drake I, Routledge PA, Richards R "Bronchospasm induced by intravenous adenosine." Hum Exp Toxicol 13 (1994): 263-5
4. Ali S, Mustafa SJ, Metzger WJ "Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine a(1) receptor." J Pharmacol Exp Ther 268 (1994): 1328-34
5. Thorne JR, Broadley KJ "Adenosine-induced bronchoconstriction in conscious hyperresponsive and sensitized guinea pigs." Am J Respir Crit Care Med 149 (1994): 392-9
6. Bennettguerrero E, Young CC "Bronchospasm after intravenous adenosine administration." Anesth Analg 79 (1994): 386-8

Therapeutic duplication

Drug classes that overlap with Adenosine + Cytochrome-C + Sodium Succinate + Nicotinamide, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antiarrhythmics
The recommended maximum number of medicines in the 'antiarrhythmics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiarrhythmics' category.
Example product in the source data (US market): Nuedexta
cardiac stressing agents
The recommended maximum number of medicines in the 'cardiac stressing agents' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'cardiac stressing agents' category.
Example product in the source data (US market): Aspirin/dipyridamole

Medicines

Food & lifestyle

coffee

Conditions

Arrhythmias, Cardiac

Cardiomyopathies

Sick Sinus Syndrome

Asthma

Therapeutic duplication

antiarrhythmics

cardiac stressing agents